Your browser doesn't support javascript.
loading
Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis.
Giordano, Gloria; Tomassini, Lorenzo; Cuomo, Ilaria; Amici, Emanuela; Perrini, Filippo; Callovini, Gemma; Carannante, Alfonso; Kotzalidis, Georgios D; De Filippis, Sergio.
Afiliación
  • Giordano G; Villa Von Siebenthal Neuropsychiatric Clinic, Rome, Italy.
  • Tomassini L; Department of System Medicine, Tor Vergata Hospital, Rome, Italy.
  • Cuomo I; ASL Roma 1, Istituto Penitenziario Regina Coeli, Rome, Italy.
  • Amici E; Villa Von Siebenthal Neuropsychiatric Clinic, Rome, Italy.
  • Perrini F; Istituto A.T. Beck-Diagnostic Centre, Research and Training in Cognitive-Behavioral Psychotherapy, Rome, Italy.
  • Callovini G; Villa Von Siebenthal Neuropsychiatric Clinic, Rome, Italy.
  • Carannante A; Villa Von Siebenthal Neuropsychiatric Clinic, Rome, Italy.
  • Kotzalidis GD; Villa Von Siebenthal Neuropsychiatric Clinic, Rome, Italy.
  • De Filippis S; NESMOS Department Neurosciences-Mental Health- and Sensory Organs, School of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Front Psychiatry ; 10: 935, 2019.
Article en En | MEDLINE | ID: mdl-31969843
Background: Long-acting injectable (LAI) aripiprazole was found to be efficacious in schizophrenia. In common clinical practice, the use of LAIs is often restricted to chronic patients with frequent relapses and poor adherence. Recently, some investigators advanced the idea of early LAI use also in young people with schizophrenia at their first psychotic episode (FEP). Objective: Our study aimed to assess the effect of LAI aripiprazole once monthly (AOM) in the treatment of FEP in patients aged 18-26 years. Methods: We included 50 patients with DSM-5 schizophrenia as assessed with SCID, and used the Clinical Global Impressions Scale-Severity of Illness (CGI-S) and the Positive and Negative Syndrome Scale (PANSS) to assess symptom severity and the World Health Organization Quality of Life (WHOQOL), the Short Form Health Survey (SF-36) and the Personal and Social Performance Scale (PSP) to assess quality of life (QoL) and global health perception at baseline and 3, 6, 9, and 12 months after the first AOM injection. Results: AOM was associated with a progressive improvement, compared to baseline, of both positive (p < 0.001) and negative (p < 0.001) symptoms and in general psychopathology (p < 0.001) and decrease in global severity (p < 0.001). We also observed progressive improvement in QoL and social and personal functioning. Treatment adherence was 78% at study endpoint. Our results support that AOM may improve psychotic symptoms, QoL and social functioning in young FEP patients. Further studies should compare AOM to its oral formulation in the treatment of young patients with schizophrenia at the outset of their illness.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Front Psychiatry Año: 2019 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Front Psychiatry Año: 2019 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza